2018
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes 2018, 67: dbi180002. PMID: 29937434, PMCID: PMC6054443, DOI: 10.2337/dbi18-0002.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Agents, ImmunologicalAutoimmune DiseasesB7-H1 AntigenDiabetes Mellitus, Type 1Genetic Predisposition to DiseaseGenotypeHLA-DR4 AntigenHumansHypoglycemic AgentsInsulinInsulin SecretionIsoantibodiesKetosisModels, ImmunologicalNeoplasmsPancreasPancreatitisProgrammed Cell Death 1 ReceptorConceptsInsulin-dependent diabetesCheckpoint inhibitorsAdverse eventsHLA-DR4Classic type 1 diabetesPD-L1 checkpoint inhibitorsEvidence of pancreatitisImmune adverse eventsSolid organ cancersType 1 diabetesPeridiagnosis periodPositive autoantibodiesL1 antibodyInsulin-DependentHigh riskPatientsDiabetesCancerInhibitorsKetoacidosisAutoimmuneAutoantibodiesPancreatitisComplicationsSyndrome
2015
Role of the Medical Oncologist in the Management of Skin Cancer
Weiss S, Wilson M, Pavlick A. Role of the Medical Oncologist in the Management of Skin Cancer. Current Dermatology Reports 2015, 4: 205-212. DOI: 10.1007/s13671-015-0119-0.Peer-Reviewed Original ResearchMetastatic skin cancerMedical oncologistsCell carcinomaSkin cancerSquamous cell carcinomaMerkel cell carcinomaBasal cell carcinomaSystemic therapyLocal therapyMedical oncologySurgical oncologyField of dermatologyCancerCarcinomaOncologistsRadiation oncologyMedical specialistsOncologyTherapyMulti-disciplinary approachPertinent evidenceSurgeryMelanomaManagementRecurrent